Efficacy and Safety of Donanemab in the Treatment of Alzheimer's Disease: A Systematic Review and Meta-Analysis
Donanemab provides statistically significant but modest benefits in early AD, particularly in low-tau subgroups. However, the magnitude of cognitive and functional improvement did not approach the threshold for a MCID in the overall population, which requires stringent safety monitoring for ARIA. Clinical implementation should prioritize PET stratification and APOEguided surveillance.
Authors
- Meiyun Zhang
- Guanqun Hu
Institutions
- Tianjin First Center Hospital (CN)
- Tianjin Medical University (CN)
Publication Details
- Journal
- Current Alzheimer Research
- Published
- 2026-03-23
- DOI
- https://doi.org/10.2174/0115672050425914260119063736
- Primary Topic
- Alzheimer's disease research and treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00